Taking antidepressants during late pregnancy. How should we advise women?

Canadian Family Physician

Volumn 51, Issue AUG., 2005, Pages 1077-1078

  Kalra, S ^a   Einarson, A ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CONSULTATION; DEPRESSION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEALTH PROGRAM; HUMAN; NEWBORN DISEASE; PATIENT COUNSELING; PATIENT MONITORING; PREECLAMPSIA; PUERPERAL DEPRESSION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; DECISION MAKING; DEPRESSIVE DISORDER; FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL ABSTINENCE SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, THIRD;

EID: 23844511337     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Buist A. Managing depression in pregnancy. Aust Fam Physician 2000;29(7):663-7.
2. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 1996;274(5288):740-3.
3. Weissman MM, Bland R, Joyce PR, Newman S, Wells JE, Wittchen HU. Sex differences in rates of depression: cross-national perspectives. J Affect Disord 1993;29(2-3):77-84.
4. Kalra SB, Sarkar M, Einarson A. Safety of antidepressants in pregnancy. Expert Opin Drug Saf 2005;4(2):273-84.
5. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335(14):1010-5. Comments i N Engl J Med 1996;335(14):1056-8, and N Engl J Med 1997;336(12):872-3; author reply 873.
6. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156(11):1129-32.
7. Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003;188(3):812-5.
8. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic, medication exposure. J Clin Psychiatry 2004;65(2):230-7.
9. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158(4):312-6.
10. Health Canada advises of potential adverse effects of SSRIs and other antidepressants on newborns [advisory]. Health Canada Online 2004(Aug 9);2004-44. Available from http://www.hc-sc.gc.ca/english/protection/warnings/2004/ 2004_44.htm. Accessed 2005 July 12.
11. Einarson A, Schachtschneider AM, Halil R, Bollano E, Koren G. SSRI's and other antidepressant use during pregnancy and potential neonatal adverse effects. Impact of a public health advisory and subsequent reports in the news media. BMC Pregnancy and Childbirth 2005;5:11.
12. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004;49(11):726-35.
13. Beck CT. Revision of the Postpartum Depression Predictors Inventory. J Obstet Gynecol Neonatal Nurs2002;31(4):394-402.
14. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001;26(1):44-8.
15. Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry 1997;58(Suppl 7):37-40.